Perform Another (Advanced) Search

1.  Study Posting (5244) Trial #163157, Diabetes Mellitus, Type 2, Hickory, NC
...Study Posting (5244) Trial #163157, Diabetes Mellitus, Type 2, Hickory, NC Trial Information DIABETES: Is metformin or metformin plus sulfonylurea the ONLY medication(s) you are taking for your diabetes? You may want ...
View Page

2.  Study Posting (5240) Trial #163158, Diabetes Mellitus, Type 2, Winston-Salem, NC
...Posting (5240) Trial #163158, Diabetes Mellitus, Type 2, Winston-Salem, NC Trial Information DIABETES: Is metformin or metformin plus sulfonylurea the ONLY medication(s) you are taking for your diabetes? You may want ...
View Page

3.  Study Posting (2249) Trial #156847, Diabetes Mellitus, Type 2, Chicago, IL
...Chicago, IL Trial Information Adults age 18-80 years with diabetes mellitus type 2 on metformin monotherapy or metformin in combination with a sulfonylurea. The effect of insulin detemir in combination with liraglutide and ...
View Page

4.  Study Posting (2829) Trial #157576, Diabetes Mellitus, Type 2, San Antonio, TX
...Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy of Saxagliptin in Combination With Metformin XR 1500 mg Versus Uptitrated Metformin XR to 2000 mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control ...
View Page

5.  Study Posting (2665) Trial #154943, Diabetes Mellitus, Type 2, Kalamazoo, MI
...This study is also being conducted to find out if taking the investigational drug with metformin alone, or with metformin plus a sulfonylurea, is better than taking insulin glargine with metformin alone or with metformin ...
View Page

6.  Study Posting (2665) Trial #154941, Diabetes Mellitus, Type 2, Kalamazoo, MI
...is also being conducted to find out if taking the investigational drug in combination with metformin is better than taking metformin alone, metformin with sitagliptin, or metformin with glimepiride. Patient Inclusion Criteria: • ≥18 years of age ...
View Page

7.  Study Posting (2348) Trial #40430, Psychosis, New York, NY
...Posting (2348) Trial #40430, Psychosis, New York, NY Trial Information A Placebo-Controlled Study of Metformin Effectiveness in Counteracting Insulin Resistance and Weight Gain in Patients Treated with Clozapine and Olanzapine. This research study is examining the effects of a medication called metformin (Glucophage) on weight gain associated with the antipsychotic medications clozapine (Clozaril) and olanzapine(Zyprexa). The ...
View Page

8.  Study Posting (1506) Trial #163386, Diabetes Mellitus, Type 2, Edina, MN
...Posting (1506) Trial #163386, Diabetes Mellitus, Type 2, Edina, MN Trial Information Do you take metformin for type 2 diabetes? If you are age 18 to 75 and take metformin (glucophage®), you may qualify for a clinical research study of an investigational medication. Qualified participants ...
View Page

9.  Study Posting (2249) Trial #156846, Diabetes Mellitus, Type 2, Chicago, IL
...Chicago, IL Trial Information Adult age 18-80 years with diabetes mellitus type 2 on metformin and pioglitazone. A multicenter, randomized, double-blind study to determine the efficacy and safety of ...
...in subjects with type 2 diabetes mellitus who have inadequate control on a combination of metformin and 30mg of pioglitazone HCl therapy. Patient Inclusion Criteria: • Male or female subjects, 18 to ...
View Page

10.  Study Posting (4519) Trial #111829, Diabetes Mellitus, Type 2, Plymouth, United Kingdom
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

11.  Study Posting (4519) Trial #111494, Diabetes Mellitus, Type 2, Northwood, United Kingdom
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

12.  Study Posting (4519) Trial #111424, Diabetes Mellitus, Type 2, Liverpool, United Kingdom
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

13.  Study Posting (4519) Trial #111687, Diabetes Mellitus, Type 2, Glasgow, United Kingdom
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

14.  Study Posting (4519) Trial #112174, Diabetes Mellitus, Type 2, Frome, United Kingdom
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

15.  Study Posting (4519) Trial #111440, Diabetes Mellitus, Type 2, Barcelona, Spain
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

16.  Study Posting (4519) Trial #112623, Diabetes Mellitus, Type 2, Bacarot Alicant, Spain
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

17.  Study Posting (4519) Trial #111890, Diabetes Mellitus, Type 2, Alzira, Spain
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

18.  Study Posting (4519) Trial #112305, Diabetes Mellitus, Type 2, Tann, Germany
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

19.  Study Posting (4519) Trial #112219, Diabetes Mellitus, Type 2, Nürnberg, Germany
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page

20.  Study Posting (4519) Trial #111489, Diabetes Mellitus, Type 2, Mannheim, Germany
...Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin Status: Completed Protocol Number: BM18249 Sponsor: Hoffmann-La Roche Company Division: Pharmaceutical Official Scientific Title ...
...and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin. Brief Summary: This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator ...
View Page